News
Evaluation of Continuity of Care in Patients with mCRC – Baseline Characteristics of Participants in the PROMETCO Study
During this year's World Congress of the European Society for Medical Oncology (ESMO) on gastrointestinal malignancies, the baseline characteristics of participants in the ongoing PROMETCO study, which focuses on evaluating the continuity of care in patients with metastatic colorectal cancer (mCRC), were presented.
Trifluridine/tipiracil in Real Clinical Practice – Current Data from Spain
Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal...
Evaluation of Treatment Response in CLL
The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these indicators...
Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?
Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to…
Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy – Results of the Final Analysis of Clinical Studies
Previously published results of clinical studies have shown that in patients refractory to…
Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against…
Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with…
Variability of COPD Symptoms During the Day and Impact on Patients' Morning Routine – Survey Results
Chronic obstructive pulmonary disease (COPD) is viewed, unlike bronchial asthma, as a condition…
Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage
The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the…
New Strategies in the Treatment of Schizophrenia
Schizophrenia was primarily associated with dopamine dysfunction. Previous and current treatments…